This study will evaluate effectiveness of etanercept with the use of 20% improvement criteria (ACR20) measured at week 12 in adults with moderate to severe Rheumatoid Arthritis. Subjects will either have failed to respond or lost satisfactory response to adalimumab, when used as their first biologic agent, in order to qualify for the study. Subject will take a stable dose of methotrexate during study (subject had to have been taking for at least 12 weeks and a stable dose of 15 mg per week for 8 weeks.)
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01927757?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
